Brazil to secure good hep C prices, but what about other expensive drugs?
This article was originally published in Scrip
The cost of hepatitis C drugs has prompted strong reactions across the world from India to Spain, but not so in Brazil where the government looks close to agreeing a favorable price with the manufacturers. Unfazed by its faltering economy and increasingly unsustainable healthcare system, Brazil's health ministry says it is set to offer free access to Bristol-Myers Squibb's Daklinza (daclatasvir), Gilead's Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir).
You may also be interested in...
The legislation will establish a new EU platform for monitoring and reporting medicines shortages.
As well as recommending Seagen’s Tukysa and Daiichi Sankyo/AstraZeneca’s Enhertu, the Scottish Medicines Consortium has given the green light to Leo Pharma’s Adtralza and a new lung cancer indication for AZ’s Tagrisso. Meanwhile, Alexion has failed to make a submission to HTAs in both Scotland and England for a specific indication for Soliris.
Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.